|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.5 USD | +0.97% |
|
+0.97% | -17.74% |
May 14 (Reuters) - The U.S. Food and Drug Administration has declined to approve the expanded use of Dynavax Technologies' hepatitis B vaccine in patients undergoing hemodialysis, the company said on Tuesday.
(Reporting by Christy Santhosh and Pratik Jain in Bengaluru; Editing by Tasim Zahid and Shilpi Majumdar)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 1,740 GBX | -1.94% | -1.97% | 92.44B | ||
| 126.1 USD | -2.63% | -3.74% | 328B | ||
| 11.5 USD | +0.97% | +0.97% | 1.49B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -17.74% | 1.49B | |
| +9.83% | 118B | |
| +10.80% | 106B | |
| -10.84% | 23.4B | |
| -1.69% | 22.1B | |
| -10.23% | 18.34B | |
| -41.92% | 16.59B | |
| -15.11% | 15.97B | |
| +6.62% | 14.03B | |
| +17.53% | 11.67B |
DYNAVAX TECHNOLOGIES CORPORATION 
